We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-11.59%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.6B
AUM Growth
-$3.29B
Cap. Flow
-$1.2B
Cap. Flow %
-8.83%
Top 10 Hldgs %
51.07%
Holding
116
New
14
Increased
50
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
+$538M
2
RHT
Red Hat Inc
RHT
+$426M
3
AABA
Altaba Inc
AABA
+$393M
4
CI icon
Cigna
CI
+$220M
5
EQIX icon
Equinix
EQIX
+$196M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$1.51B
2
ESRX
Express Scripts Holding Company
ESRX
+$1.13B
3
COL
Rockwell Collins
COL
+$584M
4
DELL icon
Dell
DELL
+$430M
5
EVHC
Envision Healthcare Holdings Inc
EVHC
+$257M

Sector Composition

Rank Sector Weight
1 Communication Services 23.71%
2 Healthcare 20.51%
3 Technology 18.84%
4 Industrials 7.34%
5 Consumer Discretionary 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
51
Exelixis
EXEL
$13.4B
$39.3M 0.29%
2,000,000
+920,000
+85% +$16.4M
RETA
52
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$39.3M 0.29%
700,000
+26,500
+4% +$1.62M
NXPI icon
53
NXP Semiconductors
NXPI
$56.9B
$39.2M 0.29%
535,000
-1,115,000
-68% -$88.3M
SAGE
54
DELISTED
Sage Therapeutics
SAGE
$38.3M 0.28%
400,000
-225,000
-36% -$25.7M
CRSP icon
55
CRISPR Therapeutics
CRSP
$5.75B
$35.7M 0.26%
1,250,000
+231,406
+23% +$8.04M
KYNB
56
Kyntra Bio
KYNB
$30.4M
$34.7M 0.25%
30,000
-25,800
-46% -$29M
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$33.7M 0.25%
2,043,149
– –
BPY
58
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
$33.4M 0.25%
2,075,000
+1,280,618
+161% +$23.4M
RC
59
Ready Capital
RC
$311M
$30.5M 0.22%
2,203,239
– –
ORBK
60
DELISTED
Orbotech Ltd
ORBK
$30.3M 0.22%
535,721
+305,721
+133% +$17.1M
FATE icon
61
Fate Therapeutics
FATE
$279M
$28.2M 0.21%
2,200,000
+1,670,000
+315% +$23.3M
PTCT icon
62
PTC Therapeutics
PTCT
$5.83B
$24M 0.18%
700,000
+280,000
+67% +$10.1M
ZYME icon
63
Zymeworks
ZYME
$2.05B
$23.1M 0.17%
1,575,000
+240,000
+18% +$3.15M
CDXS icon
64
Codexis
CDXS
$183M
$19.3M 0.14%
1,155,000
+155,000
+16% +$2.68M
ARWR icon
65
Arrowhead Research
ARWR
$12.3B
$18.6M 0.14%
+1,500,000
New +$20.5M
SVRA icon
66
Savara
SVRA
$1.15B
$18.4M 0.13%
2,425,000
+6,991
+0.3% +$62.9K
DVAX
67
DELISTED
Dynavax Technologies
DVAX
$18.3M 0.13%
2,000,000
+930,000
+87% +$10.3M
BUD icon
68
AB InBev
BUD
$155B
$18.2M 0.13%
275,843
-17,266
-6% -$1.32M
CLVS
69
DELISTED
Clovis Oncology, Inc.
CLVS
$18M 0.13%
+1,000,000
New +$20.4M
PGNX
70
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$17.6M 0.13%
4,200,820
+588,000
+16% +$2.99M
CCXI
71
DELISTED
ChemoCentryx, Inc.
CCXI
$15.8M 0.12%
1,450,000
+300,000
+26% +$3.16M
SHPG
72
DELISTED
Shire pic
SHPG
$15.2M 0.11%
87,000
– –
PTGX icon
73
Protagonist Therapeutics
PTGX
$9.99B
$14.8M 0.11%
2,199,674
-43,528
-2% -$345K
QTNT
74
DELISTED
Quotient Limited Ordinary Shares
QTNT
$14.7M 0.11%
+60,000
New +$15.7M
BMS
75
DELISTED
Bemis
BMS
$14.5M 0.11%
316,160
+109,500
+53% +$5.1M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2018 Portfolio in Review

As of Q4 2018, Thomas Steyer held 116 positions worth $13.6B, down 19% from $16.9B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer withdrew a net $1.2B in Q4 2018, closing 20 positions and reducing 18 holdings. Its most notable exit was Aetna Inc, an estimated $1.51B position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 24% of assets, up from 13% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Thomas Steyer opened a new position in Red Hat Inc worth $472M.

  • Thomas Steyer's largest Q4 2018 buy was Red Hat Inc: 2,685,000 shares worth $472M.
  • Thomas Steyer added most to Twenty-First Century Fox, Inc. Class A in Q4 2018, an estimated $538M increase.
  • Thomas Steyer's biggest Q4 2018 reduction was Dell, cutting an estimated $430M.
  • Thomas Steyer fully exited Aetna Inc in Q4 2018, selling an estimated $1.51B.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.6B portfolio in Q4 2018.
  • Thomas Steyer opened 14 new positions and closed 20 in Q4 2018.
  • Thomas Steyer's portfolio value fell 19% quarter-over-quarter to $13.6B.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.